

## AUTHORS INDEX

**Bold** numbers indicate principal authorship.

A		
ABALOS, R. M.	<b>241</b>	BALINA DE VALDEZ, M.
ABE, M.	<b>156</b>	BALSINDA, I.
ABRAAO HALLACK, K.	258	BANERJEE, D. K.
ABREU, A.	21 118 <b>291</b> 319	BAPAT, C. V.
ADAPOE, C.	119	BARANTON, G.
AGOITIA, D.	<b>220</b>	BARKSDALE, L.
AGOITIA, L.	217	BARNETSON, R. StC.
AGUIAR PUPO, J. de	<b>195</b>	BARTON, R. P. E.
AKSANOVA, R. A.	154	BASTAZINI, I.
ALAMDAROV, I. N.	<b>310</b>	BECHELLI, L. M.
ALCHORNE, M. M. A.	<b>180</b>	BEDI, B. M. S.
ALCOCER, J.	<b>89</b>	BELEHU, A.
ALEXANDER, R.	<b>99</b>	BELURKAR, B. R.
ALMEIDA BRANDAO, C. B. P.	179 <b>258</b>	BERGEL, M.
ALMEIDA PERNAMBUCO, J. C. de	96 97 169	BERNARDI, C. D. V.
ALWARENGA, A. E.	60	BERRA Y PAMIES, F. F.
AMBROSE, E. J.	<b>231</b>	BESUCHIO, S.
AMENDOLEA, M. A.	194	BHARADWAJ, V. P.
ANCHETA, O.	124	BHAT, K. R.
ANGELINI, G.	165	BHIDE, M. B.
ANGELO, M. J. de O.	206	BIANCHI, O.
ANNAMALAI, R.	<b>94</b>	BINFORD, C. H.
ANTHONY, J.	<b>192</b>	BJUNE, G.
ANTHOPOULOS, L.	253	BLOOM, B. R.
ANTIA, N. H.	231 245 <b>269</b> 276 <b>316</b>	BODDINGIUS, J.
ANTOLA, M.	333	BOGAERT DIAZ, H.
APONTE-VAZQUEZ, J.	261	BONNICI, E.
APPEL, G. E.	<b>223</b>	BONOMO, L.
APTE, N. K.	245	BORASIT, N.
ARANZAZU, N.	57 143 174 <b>240</b>	BOSE, K. S.
ARENAS, R.	221	BOUCKAERT, A.
ARVELO, J. J.	<b>317</b>	BOURGES, M.
ASSEFI, V.	<b>16</b>	BOURLAND, J.
AVALOS, E.	101 <b>150</b>	BOURREL, P.
AVILA, C.	319	BOZAN, G.
AVILA, J. J.	<b>216</b> 300	BRADLEY, D. J.
AYALA URIBE, G.	<b>20</b>	BRAGINA, V. S.
AZIZLERLI, G.	191	BRASCHER, H. M.
AZULAY, R. D.	<b>76</b> 255	BRULE, M.
AZZAM, A.	45	BURCHFIELD, H. P.
B		<b>C</b>
BABU, N. V.	<b>313</b>	CABRERA, H.
BACHMANN, A.	307	CAMPOS, F. J.
BADACHA, P.	248	CAPETANAKIS, J.
BADENOCH-JONES, P.	193	CARAYON, A.
BADOWSKAYA, Z. V.	<b>166</b>	CARDAMA, J. E.
BAGGA, V.	66	CARVALHO, R. P. de S.
BAKOS, L.	28	CASSIANO, T. P.
BALINA, L. M.	59 178 199 290 300 307 328	CASTANEDA, S.
		CASTELLAZZI, Z.
		CASTRO, E.
		CASTRO-MUSSOT, M. E.

CHACKO, C. J. G.	12	99	137	<b>246</b>	F	<b>299</b>
CHAKRABORTY, T.	236				FAJARDO, T. T.	<b>241</b>
CHAKRAVARTY, R. N.	83				FALCONE, M.	300
CHANDI, S. M.	<b>123</b>				FASAL, P.	33 212
CHAROON, P.	48				FERRACCI, C.	149
CHAROSKY, C.	<b>328</b>				FERRARA, G.	160
CHATTERJEE, B. R.	<b>109</b>	126			FERREIRA, J.	28 <b>29</b> 244
CHAUDHURY, D. S.	<b>17</b>				FESTENSTEIN, H.	12
CHAUDHURY, S.	93	<b>236</b>			FIELDS, J.	142
CHINELLI, C.	120				FINE, P. E. M.	<b>12</b>
CHIRON, J. P.	<b>37</b>				FINIAS, M.	<b>199</b>
CHOI, S. R.	<b>35</b>				FIOL, L.	300
CHOPRA, J. S.	<b>271</b>	275			FLEURY, R. N.	96 97 98 <b>169</b> <b>243</b>
CHOW, S. K. W.	<b>138</b>				FLEISSL, E.	178
CHRISTIAN, M.	<b>19</b>				FLORES, O.	220
CHULAWALA, R.	231	277			FRAGA, A.	89
CHUNG, W. K.	35				FREERKSEN, E.	<b>205</b> 287
CLOSS, O.	140	<b>144</b>	171	204	FREGNAN, R. C.	147
COLLINS, F. M.	<b>148</b>				FRIST, T. F.	<b>207</b>
COLOGLU, S.	191				FRITSCHI, E. P.	<b>210</b> 246
COLSTON, M. J.	131	<b>234</b>			G	
CONVIT, J. C.	<b>57</b>	143	157	<b>164</b>	174	290 300 307
					GABRIELLI, M.	
CORNEJO, A. L.	167				GAILHAUD, M.	175
CRAWFORD, C. L.	<b>63</b>	64	65		GAITONDE, B. B.	289
					GALLI, J. J.	<b>91</b> 324
D					GANAPATI, R.	47
DAS, P. K.	31				GANOPOL, J.	<b>333</b>
DASGUPTA, A.	192				GARCIA, M.	197
DATE, A.	259				GARCILASO, T.	221
DAVIDSON, W. S.	273				GAROFALO, M. A.	328
DELVILLE, J.	<b>105</b>	<b>126</b>			GARRISO NEVES, R.	147 <b>255</b>
DENIS, F.	37				GATTAS BARA, M.	258
DEPASQUALE, G.	<b>43</b>	287			GATTI, J. C.	59 199 <b>290</b> 300 307
DESIKAN, K. V.	108	<b>127</b>	189			328
DHOPLE, A. M.	<b>115</b>	133			GELBER, R.	<b>230</b>
DIAMANTOPOULOS, E.	44	<b>253</b>			GERBASE, A. C.	28 29
DIAZ ALMEIDA, J. G.	122	<b>124</b>			GERSHON, W.	17 <b>318</b>
DIGOUTTE, J. P.	175				GERVASI, V. S.	302
DONHAM, K. J.	70				GHOSH, S.	<b>93</b> 236
DRAPER, P.	<b>103</b>				GIRAUDEAU, P.	<b>321</b> 323
DROOGENBROECK, J. B.					GIRIJA, D.	47
A. van	270	<b>332</b>			GNENYUCK, T. S.	297
DUNCAN, M. E.	<b>86</b>	155	196		GODAL, T.	<b>139</b>
DYACHINA, M. N.	<b>166</b>				GOIHMAN-YAHR	<b>143</b> 164
					GOLOSHCHAPOV, N. M.	<b>296</b>
E					GOMEZ, M. E. de	143 164
ELLARD, G. A.	<b>225</b>				GOMEZ URCAYO, F.	<b>40</b> 219
ELSLER, E.	92				GOMEZ-V, M.	<b>327</b>
ENDO, H.	136				GONZALEZ, M. C.	160
ENNA, C. D.	<b>42</b>	263			GONZALES, O.	197
ESTEVES, M. E.	199				GONZALEZ DEL CERRO, S.	<b>213</b>
ESTRADA-PARRA, S.	150	160	168	197	GONZALEZ GALVAN, A.	<b>9</b>
					GONZALEZ-GARCIA, I.	160
EVSTRATOVA, V. A.	154	<b>311</b>				
EZER, G.	153					

GONZALEZ-MENDOZA, A.	<b>167</b>	KALOFOUTIS, A.	<b>256</b>
GOODWIN, C.S.	<b>273</b>	KAMU, I.	51
GOPINATH, P.	248	KANCHANA, K.	25 48 49
GORDON, G. R.	229 232	KANCHANA, M. V.	116 185
GRAEF, H.	205	KANTOR, I. de	<b>178</b>
GREINER, J.	<b>10</b>	KAPETANAKIS, J.	256
GRIENBERG, O.	214	KARAI, S.	<b>249</b>
GROVE, J.	229	KASAI, T.	128
GUINTO, R. S.	<b>1</b>	KASBEKAR, V.	245
GUPTE, M. D.	11 188	KATO, L.	<b>106</b> 111 119
GUZMAN, A.	89	KAUFMANN, A. E.	218
		KAUR, S.	83 271 275
<b>H</b>			
HADDAD, N.	147 <b>177</b>	KAV-VENAKI, S.	214
HAILE, G. S.	32 <b>34</b>	KAWATSU, K.	254
HANKS, J. H.	115 <b>133</b>	KHANOIKAR, S. R.	231
HARADA, K.	<b>128</b> 252	KHUTETA, K. P.	257
HARBOE, M.	<b>140</b> 144 171	KIM, D. I.	<b>176</b>
HARDWICKE, P. M. D.	63 <b>64</b>	KIM, S. J.	<b>111</b>
HARRIS, E. B.	74 110	KIRCHHEIMER, W. F.	30 <b>53</b> 74 110 114 <b>184</b>
HASTINGS, R. C.	<b>81</b> 162 200 <b>298</b>	KIEMANN, T. A. E.	<b>206</b>
HATZIS, J.	84	KLINGMUELLER, G.	<b>73</b>
HAZAMA, S.	252	KOBAYASHI, S.	272
HAZRA, S.	93	KOGAN, V. R.	154
HERBURGER MULLER, E.	36	KOHSAKA, K.	<b>55</b> 132
HERNANDEZ, O.	291	KOK, S. H.	303
HERNANDEZ SILVA, J.	301	KOLUMBAN, S. L.	<b>326</b>
HERNANDO, F.	14	KONICE, A.	153
HERRERA, M. de	59 178 199 290 307	KOSEKI, M.	252 262
HERRERA, R.	89	KOTEESWARAN, G.	<b>137</b>
HILARIO DE GONZALEZ, M.	<b>222</b>	KOTICA, K. K.	<b>46</b> 231
HILDEBRAND, W. M.	306	KOTOGLYAN, A.	153
HILSON, G. R. F.	<b>131</b> 234	KOURI, J. B.	122 124
HIRATA, T.	<b>130</b>	KRANI, P. F.	276
HONEY, N. R.	125	KREMER, A.	<b>92</b>
HOSSAIN, Z.	<b>305</b>	KRIEG, R. E.	<b>129</b>
HUIKESHOVEN, H.	<b>31</b>	KRONVALL, G.	145
		KUMAR, B.	83 271 275
<b>I</b>			
ILTER, O.	<b>153</b>	KUMAR, R.	<b>187</b>
INNAMI, S.	<b>60</b>	KUNDU, S.	93
IRGENS, L. M.	<b>6</b>	KUTEPOVA, L. G.	310
ISHAQI, M.	<b>111</b> <b>119</b>	KWAPINSKI, J. B. G.	177
ITO, T.	203		
		<b>L</b>	
JACOBSON, R. R.	<b>42</b> <b>284</b>	LAING, A. B. G.	<b>279</b> <b>294</b>
JANO, B.	33	LAKSHMINARAYANA, C. S.	<b>116</b> 185
JESUDASAN, K.	246	LANDHEER, J. E.	31
JIMENEZ-ZAMUDIO, L.	160	LANGUILLO, J.	<b>37</b> <b>292</b>
JOB, C. K.	13 123 137 246 <b>266</b> 298	LAPOSTOLLE, G.	24
JOHNEY, K. V.	259	LARCHER ALMEIDA, A. A.	258
JOPLING, W. H.	<b>242</b>	LATAPI, F.	150 201
JUAREZ MADRIGAL, M.	219	LECHAT, M. F.	<b>2</b> <b>26</b> 281
JUSCENKO, A. A.	<b>113</b>	LEFFORD, M. J.	<b>141</b>
		LEHTO, V. P.	170
		LEIKER, D. L.	31 299

LEININGER, J. R.	<b>70</b>	MOFTI, A.	<b>45</b>
LEÓN, A. P.	<b>301</b>	MOHAN, M.	<b>246</b>
LEON-MARISCAL, M. E.	<b>160</b>	MOHANTY, H.	<b>250</b>
LEVAN, N. E.	<b>182</b>	MOLERES, R.	<b>263</b>
LEVY, L.	<b>226</b> 230	MONZON, H.	<b>3</b>
LICOURT, P.	<b>319</b>	MORALEZ, M. J.	<b>200</b>
LIEW, F. Y.	<b>152</b>	MORI, T.	<b>132</b> <b>135</b> 203
LINDER, E.	<b>170</b>	MORRISON, N. E.	<b>148</b> <b>227</b>
LISKER, R.	<b>75</b>	MORROW, R. H.	<b>145</b>
LITURRI, M.	<b>308</b>	MOULDING, T.	<b>309</b>
LOBO, D.	<b>322</b>	MOYA, M.	<b>118</b>
LOGINOV, V. K.	<b>88</b>	MSHANA, R. N.	<b>144</b>
LOPEZ-BRAVO, L.	<b>51</b>	MUFTI, M.	<b>45</b>
LORIA, M. P.	<b>165</b>	MULLER, L. F. B.	<b>29</b>
LOSPALLUTI, M.	<b>165</b>	MURRAY, J. F.	<b>229</b>
LØVIK, M.	<b>204</b>	MURTI, J. M. K.	<b>271</b> 275
LOVIO, Z.	<b>118</b> 291	MZKINO, M.	<b>203</b>
LOWE, C.	<b>58</b> 71 159		
LUPPI, M.	<b>290</b> 300		
		<b>Mc</b>	
		MCADAM, K. P. W. J.	<b>163</b>
MALACARA, M.	<b>101</b>	McDOUGALL, A. C.	<b>71</b> <b>80</b> 82 279 292
MALDONADO-ROMERO, D.	<b>320</b>		
MALIK, S. K.	<b>83</b>	NAAFS, B.	<b>146</b> <b>270</b> 332
MANGHANI, D. K.	<b>277</b>	NAKAMURA, K.	<b>56</b>
MANGIATERRA, M. de	<b>215</b>	NAKAMURA, M.	<b>134</b>
MANI, R. S.	<b>17</b> 318	NAKANO, H.	<b>68</b>
MANZI, R. O.	<b>314</b>	NAKAYAMA, T.	<b>136</b>
MARGARIDO, L.	<b>102</b>	NAMBA, M.	<b>272</b>
MAR-MAR-NYEIN	<b>203</b>	NARAYANAN, E.	<b>30</b>
MARQUES, A. L. V.	<b>169</b>	NARAYANAN, R. B.	<b>188</b>
MARSELOU-KINTI, U.	<b>256</b>	NATH, I.	<b>188</b>
MARTINEZ, D.	<b>39</b> <b>85</b>	NAVALKAR, R. G.	<b>116</b> <b>185</b>
MARTINEZ JIMENEZ, A.	<b>40</b>	NAVARRETE, J. I.	<b>75</b>
MASALA, C.	<b>194</b>	NAZAROV, K. I.	<b>297</b>
MASI, D. A.	<b>224</b>	NEBOUT, M.	<b>27</b>
MASLOV, A. K.	<b>113</b>	NEELAN, P. N.	<b>8</b>
MASON, L.	<b>142</b>	NEGASSI, K.	<b>171</b>
MATHAI, R.	<b>13</b> 259	NENGERMAN, I. M.	<b>299</b>
MAUPAS, Ph.	<b>37</b>	NEVILLE, P. J.	<b>209</b> <b>315</b>
MEHRA, N. K.	<b>11</b> 67 188	NISHIURA, M.	<b>60</b>
MEHRA, V.	<b>142</b>	NOMAGUCHI, H.	<b>132</b>
MEHTA, L.	<b>245</b> 269	NOORDEEN, S. K.	<b>8</b>
MEISELS, L.	<b>214</b>	NOUSSITOU, F.	<b>280</b>
MELCHIOR, E.	<b>147</b>	NOVALES, J.	<b>239</b>
MELSON, R.	<b>155</b> <b>196</b>	NUTI, M.	<b>38</b> 181 194
MENEGRINI, C.	<b>165</b>		
MENZEL, S.	<b>145</b>	<b>O</b>	
MEYERS, W. M.	<b>54</b> 69 70 129	OCAMPO, J. C.	<b>290</b> 300
MICHALANY, J.	<b>180</b>	OCANTO, A.	<b>143</b> 164
MIGDAL, S.	<b>306</b>	OLIVARES, L.	<b>328</b>
MINEEVA, E. I.	<b>310</b>	OLIVEIRA LIMA, A.	<b>76</b>
MIRANDA, R. N.	<b>251</b>	OPROMOLLA, D. V. A.	<b>96</b> <b>97</b> <b>98</b> 169 <b>243</b>
MIRANDA, R. O.	<b>162</b>	ORTIZ, M. C.	<b>333</b>
MISSON, C. B.	<b>26</b> 281	ORTIZ, Y.	<b>167</b> 198
MITSIALI, M.	<b>186</b>	OSIPOV, A. A.	<b>260</b>
MODAK, M. S.	<b>117</b>	OZAWA, T.	<b>252</b> <b>262</b>

<b>P</b>			
PADIERRA, J.	150	<b>168</b>	201
PAGNANO, P. M. G.	147	<b>183</b>	
PALANDE, D. D.	<b>329</b>		
PALANI, N.	<b>325</b>		
PANDYA, S. S.	<b>277</b>		
PANNUTI, C. S.	206		
PARISIS, N.	<b>44</b>	84	186 253
PASCOE, J. E.	<b>65</b>		
PASQUA, J. P.	53	74	
PATTYN, S. R.	<b>237</b>	293	
PAYRO, E.	90		
PEARSON, J. M. H.	<b>4</b>	<b>32</b>	34 267
PEDROZA, E.	198		
PEREIRA, C. A. de C.	<b>179</b>	258	
PEREZ-BRICENO, R.	75		
PEREZ-SUAREZ, G.	167		
PERVUKHIN, YU. V.	<b>154</b>		
PETERS, J. H.	<b>228</b>	229	<b>232</b>
PINARDI, M. E.	57	<b>157</b>	174 240
PIZZARELLO, G. E. A.	290		
POGORELOV, V. N.	95		
PONDMAN, K. W.	31		
PONTIGGIA, S.	216		
RONZIO, H. A. S.	244		
RONZIO, T. C.	244		
PRABHAKARAN, K.	<b>110</b>		
PRACHOMPOL, O.	25	48	<b>49</b>
PRADHAN, K. S.	61		
PRITCHARD, J.	12		
PUROHIT, V. N.	<b>257</b>		
	<b>Q</b>		
QUESADA-PASCUAL, F.	150	168	<b>197</b> 198 201
	<b>R</b>		
RABELLO, F. E.	<b>77</b>		
RADHAKRISHNA, S.	19		
RADHAKRISHNAN	275		
RAIZADA, N.	<b>248</b>		
RAMANUJAM, K.	<b>79</b>		
RAMIREZ, L.	89		
RAMU, G.	108		
RAO, P. S. S.	13		
RASI, E.	14		
REA, T. H.	<b>182</b>		
RECIPON, A.	<b>211</b>		
REES, R. J. W.	32	34	<b>58</b> 66 71
	152	<b>159</b>	278 279 294
REICH, C. V.	<b>158</b>		
RICART, R.	85		
RICCIARDOCCI, R.	194		
RIDLEY, D. S.	87	159	<b>242</b>
RIDLEY, M.	<b>193</b>		
ROCHE, J. C.	175		
RODRIGUEZ, C.	<b>198</b>		
RODRIGUEZ, O.	150		
RODRIGUEZ-OCHOA, G.	143		
	<b>RODRIGUEZ PADILLA,</b>		
	A.	327	
	RODRIGUEZ-PADILLA,		
	C.	150	<b>201</b>
	ROJAS-ESPINOSA, O.	167	197 198 <b>261</b>
	ROLLIER, M.	<b>286</b>	304
	ROLLIER, R.	24	286 <b>304</b>
	ROMERO, G.	201	
	ROOK, G. A. W.	7	104 <b>151</b> 173
	ROSENFIELD, M.	205	<b>287</b>
	ROTBERG, A.	<b>15</b>	102 180
	ROUX, G.	37	
	RUBINO, M. J.	70	
	RUIBAL AREAS, B.	307	
	RUIZ DE ZARATE, S.	<b>21</b>	118 291
	RUKADIKAR, M. A.	289	
	RUSSELL, D. A.	33	50 <b>288</b>
	RYZHOOVA, N. YA.	<b>247</b>	
	<b>S</b>		
	SABAPATHY, D. S. P.	<b>23</b>	
	SAINT-ANDRE, P.	<b>149</b>	
	SAITO, T.	<b>52</b>	
	SAMSON, P. D.	<b>289</b>	
	SAMUEL, N. M.	<b>151</b>	<b>173</b>
	SANABRIA, J. N.	<b>122</b>	
	SANADA, K.	<b>252</b>	262
	SANCHEZ, R. M.	53	74 <b>114</b> 184
	SANCHEZ-CUENCA, J.	36	
	SANGARD, M.	49	
	SANSARRICQ, J.	5	
	SANTABAYA, E.	290	
	SASAKI, N.	<b>254</b>	
	SASIAIN, M. C.	<b>307</b>	
	SAUL, A.	<b>90</b>	201
	SAYLAN, T.	<b>153</b>	<b>191</b>
	SCHELLEKENS, P. TH. A.	299	
	SCHIEFER, H. B.	<b>62</b>	
	SCHLEE, P.	10	
	SCHULZ, E. J.	<b>303</b>	
	SCOLLARD, D. M.	<b>125</b>	
	SCOTT, G. C.	50	288
	SEAL, K. S.	5	
	SEBAI, Z. A.	<b>45</b>	
	SEBILLE, A.	<b>274</b>	
	SEKKAT, A.	<b>24</b>	286 304
	SEN, L.	199	
	SENGUPTA	108	
	SERIAL, A.	<b>268</b>	
	SERJEANTSON, S.	163	
	SHAH, M. N.	289	
	SHANNON, E. J.	<b>162</b>	184 200
	SHARMA, A. K.	188	
	SHEPARD, C. C.	33	288
	SHESKIN, J.	<b>214</b>	<b>282</b>
	SHETTY, V. P.	<b>269</b>	<b>276</b>
	SHIELD, M. J.	7	104 151

SHIELDS, E. D.	<b>50</b>	TUCULET, M. A.	300
SIDDHARTHA, T.	<b>66</b>	TURK, J. L.	193
SIMAO, E. T.	<b>177</b>	TURSI, A.	165
SIMMON, V. F.	<b>232</b>		
SINGH, M. P.	<b>83</b>		
SKINSNES, O. K.	<b>112</b>	ULRICH, M.	<b>174</b>
SKJÆRVEN, R.	<b>6</b>	UNDERDOWN, R.	278
SLUVKO, Z. A.	<b>88</b>	UMEROV, Z. G.	<b>235</b>
SMELT, A. H. M.	<b>152</b>		
SMIRNOVA, T.	<b>122</b>		
SMITH, S. R.	<b>163</b>	VAIDYA, M. C.	<b>11</b> <b>66</b> <b>67</b> <b>187</b> <b>192</b>
SMITH, T.	<b>10</b>		248
SOTO, J.	<b>118</b> <b>291</b>	VALDEZ, R. P.	<b>59</b>
SOTO GARCIA, G.	<b>40</b> <b>219</b>	VALDIVIA, A.	<b>21</b>
SOUZA CARVALHO, J. C. de	<b>306</b>	VAN ROOD, J. J.	<b>11</b>
SOUZA DELPINO, G. de	<b>28</b> <b>244</b>	VARGAS, P. O.	180
SPARGO, R.	<b>273</b>	VARGENS NETO, J.	<b>76</b>
SREEVATSA	<b>108</b> <b>127</b>	VARKEVISSE, C. M.	<b>208</b>
STANFORD, J. L.	<b>7</b> <b>104</b> <b>151</b> <b>173</b>	VAULA, D.	<b>6</b>
STEK, M.	<b>190</b>	VEGA-NUNEZ, J.	<b>312</b>
STENMAN, S.	<b>170</b>	VEGLIANTE, S. N.	120
STONER, G.	<b>146</b>	VELLUT, C.	<b>26</b> <b>281</b>
STORRS, E. E.	<b>72</b>	VENETSANOS, P.	<b>44</b> <b>84</b>
STRATIGOS, J.	<b>44</b> <b>186</b>	VERBINA, N. K.	310
SUDCHIT, V.	<b>49</b>	VIDYASAGAR, P. B.	276
SURASAK, S.	<b>25</b> <b>48</b> <b>49</b>	VILLALBA-PIMENTEL, L.	164
SURI, S.	<b>275</b>	VILLARREAL, J. O.	<b>41</b>
SUSHIDA, K.	<b>68</b>	VINCIN, D. R.	<b>50</b> <b>288</b>
		VINCITORIO, A. G.	<b>91</b> <b>324</b>
		VRIMOND, M. da C. L.	<b>29</b>
TAKITAKI, F. F.	<b>163</b>	VISHNEVETSKY, F. E.	<b>260</b>
TANAKA, W.	<b>232</b>	VOGEL, F.	<b>10</b>
TARABINI-CASTELLANI, G.	<b>22</b> <b>38</b> <b>181</b> <b>194</b>	VRIES, R. R. P. de	<b>11</b>
TARABINI-CASTELLANI, G. L.	<b>22</b> <b>38</b> <b>181</b> <b>194</b>		
TEERA, R.	<b>25</b> <b>48</b> <b>49</b>		
TERENCIO DE LAS AGUAS, J.	<b>36</b> <b>283</b>	WAKAMATSU, A.	<b>306</b>
THAMER, G.	<b>38</b>	WALSH, G. P.	<b>69</b> <b>229</b>
THEODORE, R.	<b>82</b>	WALSH, T. N.	<b>53</b> <b>74</b>
THOMAS, A.	<b>99</b> <b>259</b>	WALTER, J.	<b>5</b>
TIPHAGNE, J. L.	<b>18</b>	WATERS, M. F. R.	<b>87</b> <b>279</b> <b>294</b>
TIRABOSCHI-FOSS, N.	<b>183</b>	WATSON, B.	<b>12</b>
TOLENTINO, M. M.	<b>96</b> <b>97</b> <b>169</b>	WERTHEIN, L. J.	<b>21</b> <b>118</b> <b>291</b> <b>319</b>
TONELLO, C. J.	<b>96</b> <b>169</b>	WILKINSON, F. F.	<b>120</b> <b>302</b> <b>308</b>
TONETARO, I.	<b>25</b> <b>49</b>	WIT, M. de	<b>31</b>
TORRES, G.	<b>118</b> <b>319</b>	WOLF, E.	<b>12</b>
TORSUEW, N. A.	<b>95</b>	WORTH, R. M.	<b>33</b>
TOUW, J.	<b>146</b>		
TRAUTMAN, J. R.	<b>42</b>		
TRAVI, M.	<b>149</b>	YAWALKAR, S. J.	<b>292</b>
TSAMBAOS, D.	<b>256</b>	YOGI, Y.	<b>56</b>
TSVETKOVA, G. M.	<b>235</b>	ZAMBRANO, D.	<b>100</b>
		ZUNIGA, M.	<b>14</b>

## INDEX

	<i>Page</i>
<b>Session I EPIDEMIOLOGY AND CONTROL</b>	
1 Laboratory aids in epidemiology and control ...	318
2 Prospects for leprosy control ...	318
3 Primary health care and leprosy control ...	318
4 The epidemiology and some implications of sulphone-resistant leprosy ...	318
5 WHO activities in leprosy from 1973 to 1978 ...	319
6 The use of information in addition to incidence rates in the evaluation of a vaccination trial against leprosy ...	319
7 The reason for the reduction of the protective efficacy of BCG in Burma ...	319
8 Value of dapsone as a chemoprophylactic against leprosy ...	320
9 Leprosy in primary health care ...	320
10 Immunogenetic aspects of leprosy. Possible association with genes of the major histocompatibility complex (HLA, Ch, GLO I, PGM <sub>3</sub> ) ...	320
11 Evidence to demonstrate HLA-linked control of susceptibility to tuberculoid leprosy. ...	321
12 On the genetics of susceptibility to leprosy ...	321
13 Risks of treating leprosy in a general hospital ...	322
14 Distribution of leprosy in population groups at different risks — Estado Miranda, Venezuela ...	322
15 The Brazilian phase III of prevention ...	322
16 Contribution to the clinical and epidemiological study of leprosy in Iranian children ...	323
17 Perspectives in urban leprosy control ...	323
18 Leprosy survey in industries ...	324
19 Epidemiology of leprosy in South India ...	324
20 History of the official programme of leprosy control in Mexico ...	325
21 New programme of leprosy control, Cuba 1977 ...	325
22 Leprosy control campaign in Somalia. Integration into the National Health Services ...	325
23 Social aspects and epidemiology of leprosy in Sri Lanka ...	325
24 Leprosy in Morocco ...	326
25 Results of five years of integration of leprosy control into the Provincial Health Service of Phuket Island, Southern Thailand ...	326
26 Epidemiometric modelling for leprosy ...	326
27 Evaluation of mass anti-leprosy campaigns in Francophone Africa ...	327
28 Operational classification in Hanseniasis control ...	327
29 Computer usage in Hanseniasis control ...	327
30 The role of arthropods in the transmission of leprosy ...	327
31 Demonstration of dapsone in urine and serum by an enzyme-linked immunosorbent inhibition technique ...	328
32 The prevention of sulphone resistant leprosy ...	328
33 Acedapsone in the prevention of leprosy: field trial in three villages of high leprosy prevalence in Micronesia ...	329
34 Sulphone-resistant leprosy in Ethiopia ...	329
35 Incidence of hepatitis-B antigen positivity in Korean leprosy patients ...	329
36 Incidence of HBsAg and Ag 'e'/Ac anti-'e' system in a hospitalized population of patients with Hansen's disease type L ...	330
37 Hepatitis B virus indicators in leprosy ...	330
38 The e-antigen (HB <sub>e</sub> Ag) in leprosy ...	330
39 Programme of leprosy control in the Dominican Republic (1973-1977) ...	331
40 Past, present and future of leprosy in Nicaragua ...	331
41 Control of leprosy in Morelos, Mexico ...	331
42 Leprosy in the United States (1967-1976) ...	332
43 Leprosy eradication project in Malta — report after 6 years ...	332
44 Leprosy in Greece (1928-1977). An assessment of the main epidemiological characteristics of leprosy in the last 50 years ...	332
45 Preliminary study of leprosy in Saudi Arabia ...	333
46 School surveys in Bombay ...	333
47 Prevalence rate of leprosy in some urban slums — experience in Bombay ...	333
48 Comparative operational study of two methods of population survey in rural areas of Thailand ...	333
49 Some results from 20 years of leprosy control work in the Mahasarakam Province of North-Eastern Thailand ...	334
50 Leprosy in the Karimui: a genetic investigation into its susceptibility ...	334
51 Leprosy in Western Samoa ...	335
52 The present situation in Okinawa Islands ...	335

**Session II EXPERIMENTAL LEPROSY**

53	Quantitative aspects of experimental infection of armadillos with <i>M. leprae</i>	...	...	337
54	Indigenous leprosy in the nine-banded armadillo ( <i>Dasyurus novemcinctus</i> )	...	...	337
55	Nude mice for research in leprosy	...	...	337
56	The nude mouse as an experimental lepromatous leprosy model: the enhancing effect of thymus cells in infected nude mice	...	...	338
57	Experimental leprosy in <i>Dasyurus sabanicola</i>	...	...	338
58	Experimental leprosy in nine-banded armadillos imported into UK from USA	...	...	338
59	Inoculation of <i>M. leprae</i> into 3 species of autochthonous armadillos in Argentina	...	...	339
60	Study into the susceptibility of armadillos to infection by <i>M. leprae</i>	...	...	339
61	Effect of vaccine from ICRC bacilli against <i>M. leprae</i> infection in mouse footpads	...	...	339
62	Experimental transmission of a feline non-tuberculous mycobacterial skin disease resembling leprosy	...	...	340
63	Skin lesions, granulomatous hypersensitivity and cutaneous nerve damage induced by sensory peripheral nerve as antigen	...	...	340
64	The non-myelin human nerve antigen producing granulomatous hypersensitivity in rabbits	...	...	341
65	Electrophysiological studies of experimental sensory polyneuritis in rabbits	...	...	341
66	Experimental allergic neuritis	...	...	341
67	Nerve damage in leprosy — a quantitative study	...	...	341
68	Infectiousness of human leprosy bacilli in mice	...	...	342
69	Indigenous leprosy in armadillos ( <i>Dasyurus novemcinctus</i> )	...	...	342
70	Spontaneous leprosy in a chimpanzee	...	...	342
71	The histopathology of experimental leprosy in the armadillo: <i>Dasyurus novemcinctus</i> , Linn., and <i>Dasyurus sabanicola</i> , Linn	...	...	343
72	Armadillo classification and relation to humans	...	...	343
73	Inoculation of hedgehogs ( <i>Erinaceus europaeus</i> ) with <i>M. leprae</i>	...	...	344
74	Serum glycoprotein studies in armadillos experimentally infected with <i>M. leprae</i>	...	...	344
75	Distribution of pseudocholinesterase types in patients with leprosy	...	...	344
76	Chemotaxis in Virchowian Hanseniasis (lepromatous leprosy)	...	...	345

**Session III CLINICAL ASPECTS**

77	The polar concept: as it stands today	...	...	347
78	Early lesions	...	...	347
79	The Saidapet story. Findings of a nineteen year follow-up of children with untreated leprosy	...	...	347
80	The spectrum of leprosy — the intermediate zone	...	...	348
81	Reactional episodes	...	...	348
82	Clinical and histological studies of the nose in treated lepromatous leprosy	...	...	348
83	Involvement of the respiratory system in leprosy	...	...	349
84	The effect of different therapeutic regimens on the acetylcholine sweat function test (SFT) in tuberculoid leprosy	...	...	349
85	Characteristics of dimorphous leprosy in the Dominican Republic	...	...	349
86	The effect of leprosy in mothers on their children before and after birth	...	...	350
87	Tuberculoid relapse in lepromatous leprosy	...	...	350
88	Renal damage in leprosy	...	...	350
89	Inflammatory arthropathy in leprosy	...	...	350
90	The histoid nodules in lepromatous leprosy	...	...	351
91	Leprosy and the Bureau Barrière syndrome	...	...	351
92	Fundamentals of the term "Facies Antonina"	...	...	351
93	Eczema is another important complication of leprosy	...	...	352
94	Ichthyosis in Hansen's disease	...	...	352
95	Occupational allergic eczema in doctors' assistants caused by sulphurone	...	...	352
96	Involvement of the liver in leprosy reactions	...	...	353
97	Arthritis in lepromatous Hansen's disease	...	...	353
98	Squamous cell carcinoma as a complication of plantar ulcer in leprosy	...	...	354
99	A case of leprous dactylitis of all fingers in borderline leprosy	...	...	354
100	Stable tuberculoid leprosy	...	...	354
101	Stable tuberculoid leprosy	...	...	355
102	Schweninger-Buzzi type of anetodermia in Hanseniasis patients	...	...	355

**Session IV MICROBIOLOGY**

103	Studies on <i>M. leprae</i> from infected armadillos	...	...	357
104	<i>M. leprae</i> , other mycobacteria and a possible vaccine	...	...	357
105	Acid-fastness of <i>M. leprae</i> and the problems raised by its cultivation	...	...	357

106	Cholesterol, a growth factor for mycobacteria from lepromous tissues	...	...	...	358
107	Neuron invasion gene of <i>M. leprae</i>	...	...	...	358
108	Evaluation of bacteraemia in leprosy patients	...	...	...	359
109	<i>M. leprae</i> , a pleomorphic organism with a non-mycobacterial, cultivable, precursor phase	...	...	...	359
110	Rational chemotherapy of leprosy	...	...	...	359
111	<i>M. leprae</i> and the diphenoloxidase activity	...	...	...	360
112	Cultivated <i>M. leprae</i> and its antigenic reactions	...	...	...	360
113	Electronmicrochemical study of cytochrome oxidase and peroxidase of <i>M. leprae</i> , <i>M. lepraemurium</i> , <i>M. tuberculosis</i> , <i>M. kansasii</i> and <i>M. balnei</i>	...	...	...	360
114	Examination of North American armadillos for mycobacteriosis	...	...	...	361
115	Continuous <i>in vitro</i> growth of <i>M. lepraemurium</i>	...	...	...	361
116	Immunological evaluation of the ICRC bacillus — an <i>in vitro</i> isolate of <i>M. leprae</i>	...	...	...	362
117	Growth of ICRC bacilli — strain C-44 in footpads of mice	...	...	...	362
118	New experimental model for leprosy	...	...	...	363
119	Electron transport and ATP generation in host-grown <i>M. lepraemurium</i>	...	...	...	363
120	Ultrastructure of lepromatous leprosy — morphological analysis	...	...	...	364
121	Electron microscope studies of <i>M. leprae</i> during the course of its breakdown in human lepromatous tissue	...	...	...	364
122	Ultrastructural study of <i>M. leprae</i> obtained from a human leproma	...	...	...	364
123	The early cellular response to <i>M. leprae</i> — an ultrastructural study	...	...	...	365
124	Ultrastructural study of the cells in the peritoneal exudate of mice exposed to <i>M. leprae</i>	...	...	...	365
125	Cultivation of <i>M. leprae</i> from a human skin biopsy	...	...	...	365
126	Comparative skin test trial with a non-acid-fast organism isolated from lepromous tissues to establish its immunological identity with <i>M. leprae</i>	...	...	...	366
127	Viability of <i>M. leprae</i> outside the human body	...	...	...	366
128	Application of periodic acid-carbol pararosanilin stain and periodic acid-methenamine silver stain for staining leprosy bacilli in lepromous skin lesions	...	...	...	366
129	Demonstration of <i>M. leprae</i> in tissues from bacteriologically negative treated lepromatous leprosy patients	...	...	...	367
130	Cell-biological studies on the acid-fast organisms isolated and cultivated from leprosy patients	...	...	...	367
131	Freezing and storage of <i>M. leprae</i> in liquid nitrogen	...	...	...	368
132	Studies on cell culture of <i>M. leprae</i> and <i>M. lepraemurium</i>	...	...	...	368
133	Taxonomic features of <i>M. lepraemurium</i> , an obligate intracellular microbe for 69 years	...	...	...	368
134	Cultivation of <i>M. lepraemurium</i> in flask system	...	...	...	369
135	Cytochromes of <i>M. lepraemurium</i>	...	...	...	369
136	Large acid-fast bodies found in leprosy materials	...	...	...	369
137	Skin adnexa in leprosy and their possible role in dissemination of <i>M. leprae</i>	...	...	...	370
138	Secondary bacterial infections in chronic trophic ulcers in leprosy	...	...	...	370

#### Session V IMMUNOLOGY

139	Immunology of leprosy and the WHO special programme	...	...	...	372
140	A revival of interest in antibody studies in leprosy?	...	...	...	372
141	Cell-mediated immunity to <i>M. leprae</i> in mice	...	...	...	372
142	Studies on <i>M. leprae</i> -induced suppression of <i>in vitro</i> responses in leprosy patients	...	...	...	373
143	Significance of polymorphonuclear activation in reactional lepromatous leprosy. Effects of thalidomide <i>in vivo</i> and <i>in vitro</i>	...	...	...	373
144	Antigenic analysis of <i>M. leprae</i>	...	...	...	374
145	Lymphocyte transformation test in healthy leprosy contacts. Influence of household exposure	...	...	...	374
146	<i>In vitro</i> lymphoproliferative response to <i>Mycobacterium leprae</i> in normal siblings of lepromatous leprosy patients	...	...	...	374
147	Double blind trial to determine the late reactivity of leprosy patients and unaffected persons to different concentrations of armadillo lepromin in comparison to human lepromin	...	...	...	375
148	Delayed hypersensitivity responses to <i>M. leprae</i> and <i>M. vaccae</i> cytoplasmic protein antigens	...	...	...	375
149	Various methods of stimulating cell-mediated immunity in cases of lepromatous leprosy: a clinical, bacteriological and histopathological study with immunological control	...	...	...	376
150	Immunological studies in patients with indeterminate and dimorphous leprosy	...	...	...	376

151	Characterization in mouse and man of two distinct forms of delayed skin-test response, relevant to mycobacterial infections ... ... ... ... ...	377
152	Attempts to induce delayed type hypersensitivity (DTH) to <i>M. leprae</i> in healthy individuals and in "burnt-out" lepromatous patients ... ... ... ...	377
153	Immunological findings in lepromatous leprosy ... ... ... ...	378
154	On the assessment of immunological status of lepromatous patients ... ...	378
155	Foetal immunity in leprosy: lymphocyte responses to <i>M. leprae</i> and phytohaemagglutinin in mother and baby at the time of birth ... ...	378
156	Fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with <i>M. leprae</i> ... ... ... ...	379
157	Conversion of Mitsuda negative normals into Mitsuda positive through repeated testing with diverse antigens ... ...	379
158	A specific leprosy antigen isolated by affinity chromatography using gel immobilized lepromatous IgG as the stationary phase ... ...	380
159	Immunological studies in guinea pigs and in man on bacteria and cell-free extracts of purified armadillo-derived (PAD) <i>M. leprae</i> ... ...	380
160	MIF response to lepromin, PPD and SK-SD in patients with lepromatous leprosy and healthy individuals ... ...	380
161	Comparative study on skin reactions to <i>M. leprae</i> -lepromin and to ICRCin — an antigen from cultivable acid-fast bacilli from <i>M. leprae</i> isolated from lepromatous nodules ... ...	381
162	The effect of thalidomide on <i>de novo</i> antibody synthesis ... ...	381
163	The effect of colchicine on serum amyloid A elevation during erythema nodosum leprosum reactions ... ...	382
164	Neutrophil activation in adjuvant disease. Its implications for reactional lepromatous leprosy ... ...	382
165	Humoral and cellular immunity in lepromatous leprosy ... ...	382
166	Immunochemical study of mycobacterial antigens ... ...	383
167	Demonstration of intracytoplasmic <i>M. leprae</i> antigen in the inflammatory exudate of reactional lepromatous leprosy ... ...	383
168	Determination of T and B lymphocytes in patients suffering from different types of leprosy ... ...	383
169	Anti-connective tissue antibodies in leprosy ... ...	384
170	Antibodies reacting with fibroblasts, Schwann cells and connective tissue microfibrils in leprosy ... ...	384
171	Cross-reactions between serum proteins and liver tissue antigens of the nine-banded armadillo ( <i>Dasypus novemcinctus</i> Linn.) and man. The implications for leprosy research ... ...	385
172	Lymphocyte function in progressive <i>M. lepraemurium</i> infection ... ...	385
173	An investigation of mechanisms regulating skin test responsiveness in leprosy patients using soluble <i>M. leprae</i> and <i>M. tuberculosis</i> antigens and a mixture of the two ...	385
174	Skin-reactive antigens of <i>M. leprae</i> ... ...	386
175	Study of the immunity, after an interval of 3 years, of leprosy patients having undergone BCG immunotherapy ... ...	386
176	BCG immunotherapy trial in lepromatous leprosy ... ...	387
177	Double blind trial on the effect of certain soluble cytoplasmic mycobacterial antigens on the reactivity to lepromin ... ...	387
178	Protein derivative prepared from <i>M. leprae</i> suspensions maintained in a semi-synthetic medium ... ...	387
179	Mitsuda antigen of animal origin. Absence of Hanseniosis in armadillos living in the natural state; human hypersensitivity to the animal antigen ... ...	388
180	Prognostic considerations based on a study of 38 Hanseniosis patients submitted to Mitsuda tests 23 to 35 years previously ... ...	388
181	Results of the lepromin test using human lepromin (H) and armadillo lepromin (A) ...	389
182	Dinitrochlorobenzene responsitivity throughout the granulomatous spectrum of leprosy ... ...	389
183	Lymphocyte transformation test (LTT) in leprosy patients, in the presence of phytohemagglutinin, lepromin and <i>M. leprae</i> , in culture medium with normal homologous serum ... ...	389
184	Effect of specific vaccine on cell-mediated immunity of armadillos against <i>M. leprae</i> ...	390
185	Antigenic evaluation of <i>Mycobacterium vaccae</i> — a mycobacterium possibly related taxonomically to <i>M. leprae</i> ... ...	390
186	FLA-ABS test as a screening test for the detection of cases at an early stage of leprosy ...	391

187	Morphological changes in mast cells and levels of serotonin and histamine in leprosy patients	391
188	Suppressor cells in human leprosy	391
189	Fluorescent leprosy antibody absorption (FLA-ABS) test for early serodiagnosis of leprosy	391
190	Micro-technique enzyme-linked immuno-sorbent assay of C1q-reactive circulating immune complexes in leprosy	392
191	Direct and indirect immunofluorescent studies of the lesions, normal skin and sera of leprosy patients	392
192	Immune complexes in erythema nodosum leprosum	393
193	Cellular responses in leprosy and related diseases with particular reference to cells of the mononuclear phagocyte series	393
194	Auto-antibodies in leprosy	393
195	Ancestral immunity in the evolution of endemic leprosy in the tropical zones	393
196	Immunoglobulin concentration in mothers and in healthy controls and their babies at the time of birth	394
197	A comparative serum profile in leprosy-related and non-leprosy-related families	394
198	The immunological profile of patients with different types of leprosy resident in a hospital for the treatment of leprosy	394
199	Importance of the effect of Levamisole on lymphocytes in household contacts of bacilliferous lepromatous patients	395
200	Studies on the anti-inflammatory mechanism of action of thalidomide in leprosy	395
201	Immunological studies in leprosy patients in leprosy reaction treated with thalidomide	396
202	<i>In vitro</i> lymphocyte responses in borderline leprosy reactions	396
203	Antigenic substances of <i>M. leprae</i>	397
204	Dissociation in mice between delayed type hypersensitivity to a sonic extract of <i>M. leprae</i> (MLM) and resistance to MLM infection	397
205	The role of thymectomy and whole body irradiation on the development of immunity to mycobacterial infections	397
206	Rubino's reaction by microtechnique with sheep and horse erythrocytes	397

**Session VI SOCIAL ASPECTS**

207	Community factors influencing the leprosy patient and his treatment	400
208	The methodology of investigating social aspects of leprosy work	400
209	Non-medical objectives of a leprosy control programme	400
210	Employment and re-employment	401
211	World Leprosy Day	401
212	The several faces of leprosy	401
213	Stigma and leprosy	402
214	Leprosy stigma and its effects on patients' self-concept and attitudes towards society	402
215	The term <i>leprosy</i> carries prejudice	403
216	Psychological rehabilitation of leprosy patients using group dynamics	403
217	The mental state of the patient with leprosy	403
218	Leprosy: social change and social class	403
219	Psycho-social change in leprosy in the National Dermatological Centre of Nicaragua	404
220	The social aspects in 1063 cases of leprosy	404
221	Domiciliary visiting in cases of leprosy	404
222	Importance of methods of communication in the fight against leprosy. Experiment in the Dominican Republic (1966-1977)	405
223	Social aspects of leprosy in Pará State, Amazon Valley	405
224	The Leprosy Board of Paraguay — present programme of leprosy control	405

**Session VII EXPERIMENTAL CHEMOTHERAPY**

225	Pharmacological considerations of drug combinations for the treatment of lepromatous leprosy	408
226	Persistence and drug resistance of <i>M. leprae</i> — major obstacles to successful chemotherapy of lepromatous leprosy	408
227	Mechanism of action of clofazimine	408
228	Tissue levels of dapsone during combined dapsone-rifampin therapy	408
229	Metabolic disposition of dapsone (DDS) and rifampin (RFM) in nine-banded armadillos ( <i>Dasypus novemcinctus</i> )	409

230	The activity of dihydrofolate reductase inhibitors against <i>M. leprae</i> infection of the mouse footpad	409
231	An <i>in vitro</i> test for drug response and drug resistance of <i>M. leprae</i> using labelled metabolites	410
232	Mutagenesis-carcinogenesis of antileprosy drugs in animal systems: pertinence to man	410
233	Carcinogenic activity of dapsone	410
234	The effect of intermittent ethionamide and combinations of ethionamide and dapsone in experimental leprosy in mice	411
235	Effect of Sulphetrone treatment on pathological changes of the deep organs of mice infected by passage strain of <i>M. leprae</i>	411
236	"Mandukaparni" — a common Indian herb effective against leprosy	411
237	The activity of combined drugs on <i>M. leprae</i> in mice	412

**Session VIIIA CLINICO-PATHOLOGICAL ASPECTS**

238	The contribution of histology in the early diagnosis of leprosy	414
239	Lucio leprosy	414
240	Clinico-pathological aspects of leprosy	415
241	A study of proven dapsone-resistant leprosy in Cebu, Philippines	415
242	Classification of leprosy: three instructive cases	415
243	The clinical spectrum of leprosy	416
244	Clinical and histological evaluation of 417 suspected cases of Hanseniasis	416
245	Evolution of nasal mucosal lesions in leprosy — histopathological study	416
246	Primary leprosy involvement of nasal mucosa in apparently healthy household contacts of leprosy patients	417
247	Clinical and biochemical aspects of leprosy	417
248	$^{99m}$ TcO <sub>4</sub> brain scan in <i>M. leprae</i> infection	418
249	Aetiology of bone changes in the foot in leprosy: a population-based study	418
250	Renal dysfunction in leprosy	418
251	Lucio's phenomenon in tuberculoid leprosy	418
252	Relapse in lepromatous leprosy	419
253	Coronary heart disease in leprosy patients	419
254	Remnants of leprosy bacilli in deep organs of patients having had lepromatous leprosy, now quiescent — use of improved acid-fast staining method	419
255	The importance of lipid staining in the classification of leprosy	420
256	The phospholipid composition of leucocytes in lepromatous leprosy	420
257	Blood sialic acid (N-acetyl neuraminic acid — NANA) levels in cases of leprosy — a diagnostic and therapeutic tool	420
258	Immune complex deposit in Hanseniasis: a percutaneous renal biopsy study	421
259	Renal changes in leprosy	421
260	Esterase spectrum in epidermal cells and infiltrates in lepromatous skin lesions	421
261	Phagocytosis in leprosy. Endocytic ability of peripheral blood leucocytes as measured by its capacity to ingest <i>M. lepraemurium</i> <i>in vitro</i>	422
262	PHA skin test in leprosy patients, compared with other delayed type hypersensitivity skin tests	422
263	Acro-osteolysis in Hansen's disease	422

**Session VIIIB CLINICO-PATHOLOGICAL ASPECTS: NERVE DAMAGE**

264	Ultrastructure of beginning and progressive nerve involvement in leprosy patients	425
265	Pathological and haemodynamic bases of nerve decompression	425
266	Pathological and immunological basis of medical intervention in lepromatous neuritis	426
267	Nerve damage in leprosy: prospects for study and applications for therapy	426
268	Neuritis after intradermal tests with <i>M. leprae</i> in patients with tuberculoid leprosy	426
269	Evolution of nerve lesions in leprosy	427
270	Assessment of nerve function in leprosy	427
271	Motor nerve conduction velocity in leprosy and its correlation with clinical and histological findings	427
272	Involvement of cranial nerves in leprosy with reference to treatment	428
273	Symptomatic neuritic leprosy precipitated by rifampicin and isoniazid treatment of tuberculosis, and rifampicin-associated neuritis	428
274	Electrophysiological evidence for motor-unit impairment during the treatment of leprosy	428

275	Peripheral vascular deficit in leprosy and its role in the pathogenesis of neuropathy ...	429
276	Segmental demyelination in leprosy in the human and the mouse model as assessed by teased fibre technique with electrophysiological correlation ...	429
277	Correlations of <i>in vitro</i> electrophysiological, light and electronmicroscopical studies in the neuropathy of leprosy ...	430
278	Ultrastructural changes in blood vessels of peripheral nerves and of skin in leprosy patients ...	430

**Session IX THERAPY**

279	The problem of microbial persistence in leprosy ...	432
280	Therapy of leprosy ...	432
281	Maintenance therapy in non-lepromatous leprosy ...	432
282	The treatment of lepromatous leprosy reaction, with special reference to thalidomide ...	433
283	Results of long-term sulphone therapy for lepromatous leprosy with special reference to renal abnormalities and to the frequency of drug resistance ...	433
284	The treatment of sulphone-resistant leprosy ...	433
285	The treatment of reversal reactions ...	434
286	Relapse and dapsone resistance in Morocco ...	434
287	Practical experience with combined therapy in leprosy ...	434
288	Status at ten years of the leprosy patients in the acedapsone (DADDS) trial in the Karimui, New Guinea ...	435
289	Acedapsone in the treatment of 70 lepromatous patients ...	435
290	Rifampicin in the treatment of lepromatous leprosy ...	436
291	Treatment with rifampicin of 5000 leprosy patients in Cuba ...	436
292	Therapeutic effects of adding Rimactane <sup>R</sup> (rifampicin) 450 mg daily or 1200 mg once monthly in a single dose to dapsone 50 mg daily in patients with lepromatous leprosy ...	436
293	Short course rifampicin treatment of TT and BT leprosy ...	437
294	Four-weekly 'pulse' therapy with rifampicin in sulphone-resistant lepromatous leprosy — interim report ...	437
295	Results of the treatment of leprosy patients with prothionamide ...	437
296	Diuciphon (Diuciphonum) — experimental and clinical data ...	438
297	The results of immunotherapy of patients with lepromatous leprosy ...	438
298	Histopathologically documented reversal reaction in lepromatous leprosy following treatment with transfer factor ...	439
299	A placebo-controlled clinical trial of transfer factor in lepromatous leprosy ...	439
300	Leprosy reaction and Levamisol (R 12564) ...	440
301	Pilot trial of short treatment of leprosy by associated chemotherapy and immunotherapy ...	440
302	Study of the action of 2-mercaptopropionil glycine on leprosy ...	440
303	Treatment of lepromatous leprosy with long-acting sulphonamides ...	440
304	Comparative study of five groups of patients: dapsone with another drug ...	441
305	Dimocifon in the treatment of leprosy patients ...	441
306	Therapeutic trial with immunomodulators in Hanseniasis — Levamisol and Tetramisol ...	441
307	The immunomodulatory action of two drugs given together in bacilliferous lepromatous leprosy ...	442
308	The combination rifampicin-Levamisol in a double-blind trial in the treatment of lepromatous leprosy ...	442
309	A medication monitor for studying compliance with anti-leprosy drug regimens ...	443
310	The treatment of leprosy neuritis ...	443
311	Comparative assessment of various methods of treatment in leprosy ...	443
312	Sulphone-resistant leprosy: a case communication ...	444
313	Clinical trial of rifampicin in lepromatous leprosy ...	444

**Session X REHABILITATION**

314	Planning the rehabilitation of patients with leprosy ...	446
315	Health education ...	446
316	The role of surgery in leprosy rehabilitation — a general overview ...	446
317	The prevention of disability in patients with leprosy ...	447
318	Leprosy rehabilitation: a pragmatic approach in a developing country ...	447
319	Medical and socio-economic rehabilitation of leprosy patients in Cuba ...	447
320	Social rehabilitation of the patient with leprosy ...	448

321	The place and importance of surgery in leprosy within a national programme of leprosy control	448
322	Disabilities, displacement and role of reconstructive surgery in leprosy	448
323	Twenty years of surgery at the Institut Marchoux at Bamako	449
324	Neuropathic foot in leprosy	449
325	The protection of anaesthetic limbs of patients living in rural areas in developing countries	449
326	A method for standardizing physiotherapy assessments	450
327	Hand lesions in Hansen's disease	450
328	Compression neuropathy of the radial nerve in leprosy	450
329	Surgical treatment of ulnar nerve paralysis in leprosy	451
330	Decompression in leprosy neuritis as a therapeutic and preventive measure	451
331	Adaptation of decompression methods to the clinical form of neuritis	451
332	Nerve surgery in leprosy	452
333	Neuropathy in leprosy: results of surgical treatment	452